Strong collaborations drive new possibilities in #CancerCare. At #ESMO26, we, along with our research collaborators, will present 25 abstracts, including 5 rapid oral presentations, exploring advances in liquid biopsy across lung, colorectal, & gastric cancers. Reflecting the strength of our biopharma, academic, & public-private partnerships, these findings expand the evidence across MRD surveillance, treatment response, and resistance research, advancing our understanding of how genomic and epigenomic insights can inform cancer care. Details: bit.ly/486gejw

#NewData reinforces the potential of Shield™ to close gaps in #ColorectalCancer screening, with 99% screening adherence in two rural clinics serving medically underserved communities and modeling results projecting more colorectal cancer deaths averted with blood-based screening than stool-based tests. Presented with our research collaborators at #ACG2026, this new modeling data builds on the growing evidence supporting Shield’s role in expanding screening participation and improving health outcomes. More: bit.ly/4s7DwyB

Guardant360® CDx’s 31st companion diagnostic approval marks another #Milestone in its growing role in cancer care. Guardant360 CDx has received approval in Europe as a companion diagnostic to identify patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from @AstraZeneca's ETCAMAH™ (camizestrant). Following approvals in the U.S. and Japan, this milestone reinforces our commitment to enabling practice-changing ongoing monitoring across the world’s largest healthcare markets. More: bit.ly/4AXzGfx

Understanding melanoma recurrence risk after surgery can help shape what comes next for patients. New results from the COSMOS-MEL01 study, published in @CRC_AACR, expand the evidence supporting Guardant Reveal® for molecular residual disease detection and recurrence monitoring in melanoma. The study demonstrated 81% sensitivity for distant recurrence and 100% post-treatment specificity, highlighting the potential of Reveal to inform more personalized surveillance strategies. More: bit.ly/3Vt96uM

#AI is everywhere—but where is it making an impact in drug discovery and development? At the 16th World Clinical Biomarkers & Companion Diagnostics Summit, we’ll share how InfinityAI and our multiomic data are helping researchers navigate complex biological datasets, accelerate hypothesis generation, and uncover new opportunities for therapeutic development. Join us in Boston: world-cdx.com/

Our Chairman and co-CEO Helmy Eltoukhy joined @CNBC this morning to discuss how blood-based testing can help physicians identify molecular resistance in metastatic #BreastCancer—moving cancer care from one step behind to one step ahead.

We’re proud to sponsor the 2026 @NCQA Health Innovation Summit in Atlanta. We look forward to connecting with leaders advancing quality, digital transformation, and innovation across healthcare, and discussing how blood-based #ColorectalCancer screening can accelerate adoption and reduce barriers in population health strategies. #NCQASummit

#NewResearch in @JCOPO_ASCO highlights the prognostic value of tissue-free MRD testing. In an analysis of samples from the SUCCESS-A trial, Guardant Reveal® detected molecular residual disease approximately two years after adjuvant chemotherapy, with ctDNA positivity strongly associated with later distant recurrence. Read more: bit.ly/4gY28pT

#Coverage for the Shield™ blood test for #ColorectalCancer screening continues to expand. Starting January 1, 2027, @evicorehc —the second-largest national medical benefit manager in the U.S.—will cover Shield for eligible policyholders, bringing Shield coverage to approximately 94 million Americans ages 45 and older. Details: bit.ly/4htyw3J

How can a blood test help clinicians monitor changes in cancer? On @CNN's The Situation Room this morning, our Chairman and co-CEO Helmy Eltoukhy joined @PamelaBrownCNN to discuss the first-of-its-kind FDA approval of Guardant360® CDx as a companion diagnostic for AstraZeneca’s ETCAMAH™—and its potential to advance more precise, proactive cancer care for certain patients with advanced #BreastCancer. Watch the full segment: bit.ly/4gU5JVN

With more screening options, we can reach the 54 million people who have forgone or delayed their critical #ColorectalCancer screening. Listen below to hear from our Co-CEO AmirAli Talasaz on how blood-based screening options like Shield™ have been proven to help close CRC screening gaps:

We’re heading to Seoul this week for #WCLC26, hosted by @IASLC Together with our research collaborators, we’ll present 20 abstracts highlighting advances in liquid biopsy across #LungCancer, including tissue-free MRD surveillance, treatment-response and resistance research, and investigational early-detection. Details: bit.ly/3SQYODJ

Today, the FDA approved Guardant360® CDx as a companion diagnostic for @AstraZeneca's ETCAMAH™ (camizestrant) in advanced #BreastCancer, representing a major shift toward adaptive cancer management and earlier interception of disease progression based on a blood test. “This approval represents a fundamental shift in how we can stay ahead of breast cancer," added our Chairman and co-CEO Helmy Eltoukhy. "For decades, doctors have largely waited for a scan to show that a tumor has grown before changing treatment. Now, a simple blood test can detect the molecular signs that a cancer is beginning to escape treatment, months before that progression may be visible on a scan, giving doctors an opportunity to switch therapy while the disease is still under control." Details: bit.ly/4qZZVxA

#Innovation matters most when it makes a difference for patients. @BusinessInsider has named us one of America’s Most Innovative Businesses for 2027 with a five-star rating awarded to only 10 companies in the biotechnology category, reflecting the innovative science and technology driving our work across #CancerCare. Recognition marks a moment. Innovation is about what comes next. Details: bit.ly/4hbFave

Behind every life lost to #ColorectalCancer is a story, a family, & a legacy that lives on. Our co-CEO AmirAli Talasaz reflects on the lives and legacies of those who have passed from colorectal cancer & how their stories reinforce the importance of raising awareness, expanding screening options, & continuing the work to change the future of colorectal cancer.